About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

- Claus Andersson, PhD, joins Rewind´s Board of Directors

Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors. Financial details of the transaction were not disclosed.

The proceeds will be used to advance Rewind Therapeutics´ lead program into clinical development and further broaden the Company´s pipeline of drug candidates designed to restore the remyelination function of the central nervous system (CNS). Myelin forms a protective layer around neurons and is essential for their proper functioning. Neurodegenerative disorders such as multiple sclerosis are associated with a damaged, deteriorating myelin sheath, which ultimately leads to a range of symptoms such as depression, anxiety, irritability, and even death due to a breakdown of the vital neurological functions.

"We are delighted to welcome Sunstone Life Science Ventures as a new investor alongside the continued support by our existing investor syndicate," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics. "The additional financing not only strengthens our top-tier investor base, but also allows us to accelerate the progression of our lead program into clinical development. Moreover, we look forward to working with Claus Andersson as a new member of our Board of Directors."

"Halting or even reverting demyelination is a challenging task. The data generated by Rewind Therapeutics so far supports a truly novel mechanism of action and will allow the Company to initiate clinical trials in key CNS indications," said Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S. "Moreover, Rewind has a strong patent estate and a team with long research and development expertise in the field of remyelination therapeutics. The combination of this extensive industry expertise and the high unmet medical need in neurogenerative disorders has convinced us to join forces with Rewind´s existing, internationally renowned investor syndicate."

Demyelinating diseases such as multiple sclerosis affect millions of patients worldwide. Rewind´s approach is based on ensuring proper functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs), both of which are drivers of the myelination process. The Company´s goal is to establish a novel therapeutic principle that is universally applicable to all demyelination diseases. This provides significant therapeutic potential for treating a broad range of demyelination-inducing conditions.

###

About Rewind Therapeutics
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries. A common feature of these illnesses is the loss of the myelin sheath, a protective cover wrapped around the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or reversing disease progression or even curing these diseases. Rewind´s team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Sunstone Life Science Ventures, Gemma Frisius Fonds, and CD3/ KU Leuven.
https://rwdtx.com/

About Sunstone Life Science Ventures
Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone Life Science Ventures focuses on developing and expanding early‐stage Life Science companies with strong potential to achieve global
success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. For more information, please visit: https://sunstone.eu/

For further information please contact:
Rewind Therapeutics
Anja Harmeier
Chief Executive Officer
info@rwdtx.com

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.